Skip Navigation

Annals of Oncology 2004 15(12):1847-1848; doi:10.1093/annonc/mdh478
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ferretti, G.
Right arrow Articles by Cognetti, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferretti, G.
Right arrow Articles by Cognetti, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 European Society for Medical Oncology

Zoledronic acid-associated thrombotic thrombocytopenic purpura

The first 10% of the full text of this article appears below.

Although many cases are idiopathic, thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) sometimes occurs in association with cancer, drugs (cyclosporine A, mitomycin, quinine, ticlopidine, clopidogrel), pregnancy, autoimmune diseases, infection and bone marrow transplantation [1Go]. This clinical heterogeneity poses a challenge to understanding the pathogenesis of TTP and selecting appropriate therapies.

We . . . [Full Text of this Article]

G. Ferretti1,*, M. C. Petti2, P. Carlini1, M. Zeuli1, A. Picardi3, G. Meloni4, E. Bria1, P. Papaldo1, A. Fabi1 and F. Cognetti1

1 Department of Medical Oncology, Regina Elena Cancer Institute, Rome; 2 Division of Hematology, Regina Elena Cancer Institute, Rome; 3 Division of Hematology, University Tor Vergata, Rome 4 Division of Hematology, University La Sapienza, Rome, Italy

* Email: gia.fer@flashnet.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BMJ Case ReportsHome page
S. K Bhadada, A. Bhansali, S. Das, A. R, and S. D Rao
Thrombotic thrombocytopenic purpura following zoledronic acid infusion with a fatal outcome
BMJ Case Reports, March 30, 2009; 2009(mar30_1): bcr0920080923 - bcr0920080923.
[Abstract] [Full Text]

Home page
 Ann OncolHome page
T. Tanvetyanon and P. J. Stiff
Management of the adverse effects associated with intravenous bisphosphonates
Ann. Onc., June 1, 2006; 17(6): 897 - 907.
[Abstract] [Full Text] [PDF]